;
Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Figure: London vs. Europe

    Small but mighty London vs. Europe The BioCentury Europe index gained 4% in 1Q14, while the BioCentury London index declined by 2%. Fifteen of 19 continental European biotechs in the market cap-weighted BC Europe …

    Published on 4/7/2014
  • Figure: Price-to-earnings: BT vs RX

    Small but mighty Price-to-earnings: BT vs RX The average biotech P/E ended the quarter at 27.4, about 1.6x big pharma's average P/E of 17.3. But biotech's average multiple drops to 22.2, only 1.28x that of big …

    Published on 4/7/2014
  • Figure: Results by market cap

    Small but mighty Results by market cap The two smallest market cap segments - companies valued below $200 million and those valued at $200-$499 million - each rose more than 5% last quarter on a deluge of IPOs. In …

    Published on 4/7/2014
  • Table: 1Q approvals and 1Q setbacks

    Small but mighty 1Q approvals Selected first quarter approvals. Company Approval Anika Therapeutics Inc. (NASDAQ:ANIK)/Johnson & Johnson (NYSE:JNJ) FDA approves Monovisc to treat osteoarthritis of the knee …

    Published on 4/7/2014
  • Table: 2Q milestones

    Small but mighty 2Q milestones Selected products with Phase III or regulatory milestones expected in 2Q14. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone AcelRx …

    Published on 4/7/2014
  • Table: Index performance

    Small but mighty Index performance The BioCentury 100, NYSE Arca Biotechnology (BTK) and NASDAQ Biotechnology (NBI) were not in lockstep in 1Q due to differences in the indices' makeup. The BC100 and BTK rose 10% …

    Published on 4/7/2014
  • Table: Restructuring watch

    Small but mighty Restructuring watch Only two companies reported workforce reductions in the first quarter compared to at least 10 in the same period last year. This is the smallest number since BioCentury started …

    Published on 4/7/2014
  • Banker tracks

    Biotech investor, banker and analyst personnel changes

    Ebb & Flow Banker tracks Former ABN AMRO executive directors Maurice Laudy and Machiel van Oostveen launched healthcare advisory firm Saola Healthcare Partners. Saola's focus includes life sciences, medtech, …

    Published on 3/31/2014
  • Slip-sliding

    Biotech slumps on rotation to value, but buysiders say fundamentals still strong

    Ebb & Flow Slip-sliding Figure: IBB fund flows Figure: Money Raised in 2014 Sector-specific concerns plus an investor rotation out of growth stocks have sent biotech shares tumbling. Buysiders think the slide is a…

    Published on 3/31/2014
  • Fast out of gate

    Early exits from first fund bring investors back for more in Ysios BioFund II

    Ebb & Flow Fast out of gate A few early wins in Ysios Capital's 2008 vintage venture fund have existing LPs looking to make bigger contributions to the firm's second fund. The Spanish firm hopes to repeat the …

    Published on 3/31/2014
  • Figure: IBB fund flows

    Slip-sliding IBB fund flows The iShares Nasdaq Biotechnology (IBB) ETF has attracted net cash inflows of $451.2 million this year, even though $66.1 million has exited the ETF over the last two weeks. IBB has traded…

    Published on 3/31/2014
  • Figure: Money Raised in 2014

    Slip-sliding Money Raised in 2014 Last week, the biotech industry raised $456 million, bringing to $18.7 billion the total raised year-to-date. In 2013, a total of $36.9 billion was raised, including $14.4 billion …

    Published on 3/31/2014
  • Doubling up

    Endocyte tops up after stock jumps on Vynfinit CHMP nod, NSCLC data

    Ebb & Flow Doubling up Endocyte Inc. (NASDAQ:ECYT) wasted no time padding its coffers after its stock almost doubled on a nod from EMA's CHMP for Vynfinit vintafolide and data in non-small cell lung cancer (NSCLC).…

    Published on 3/31/2014
  • LSP's steady hand

    How LSP has survived 25 years as European life sciences VC

    LSP has survived 25 years as a life sciences VC by making a few small changes to an otherwise single-minded strategy focused on investing in early stage European biotechs.

    Published on 3/31/2014
  • Table: LSP exits

    LSP's steady hand LSP exits LSP-Life Sciences Partners has had 12 exits in the past 18 months, almost the same number as in 2006-11. Sources: LSP; BCIQ: BioCentury Online Intelligence Company Business Exit Deal …

    Published on 3/31/2014
  • Highlights of weekly biotech stock moves

    Regulatory, clinical and other milestones

    Ebb & Flow Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) gained $0.60 to $7.20 last week after resubmitting an NDA to FDA for Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular…

    Published on 3/31/2014
  • Breaking out

    Why Breakout Labs, NetScientific teamed up to boost early stage companies

    Ebb & Flow Breaking out NetScientific plc (LSE:NSCI) hopes a deal with The Thiel Foundation's Breakout Labs will expand the biotech IP commercialization firm's reach in terms of geography and stage of development. …

    Published on 3/31/2014
  • Venture tracks

    Biotech investor, banker and analyst personnel changes

    Ebb & Flow Venture tracks Michael Wiley joined Foundation Venture Capital Group LLC as senior director of ventures and commercialization. Wiley was a senior venture officer, a clean energy solutions project leader …

    Published on 3/24/2014
  • Figure: Money Raised in 2014

    Horizon's Irish jig Money Raised in 2014 Last week, the biotech industry raised $783 million, bringing to $18.2 billion the total raised year-to-date. In 2013, a total of $36.9 billion was raised, including $14.4 …

    Published on 3/24/2014
  • Quick turn

    How Atlas repackaged Saniona assets and set up an exit path within a year

    Ebb & Flow Quick turn In less than a year, Atlas has set up a potential exit for Ataxion Inc. via a $17 million tranched series A round that will fund the company through completion of a Phase I study of an …

    Published on 3/24/2014
  • Modulating sepsis

    Rationale for investing EUR 18 million in preclinical sepsis play Inotrem

    Ebb & Flow Modulating sepsis Sepsis is among the most intractable indications in drug development, but Inotrem S.A. and its series A investors think the company's peptide inhibitors of TREM1 may succeed where all …

    Published on 3/24/2014
  • Highlights of weekly biotech stock moves

    Regulatory, clinical and other milestones

    Ebb & Flow Regulatory milestones AB Science S.A. (Euronext:AB) fell €1.61 (11%) to €12.67 on Friday after EMA's CHMP again recommended against conditional approval of masitinib for second-line treatment of …

    Published on 3/24/2014
  • Rosetta (mile)stones

    Rosetta gets more clinical-stage assets with secondary purchase from pharma VC

    Ebb & Flow Rosetta (mile)stones Rosetta Capital Ltd.'s latest secondary equity acquisition fits into the firm's wheelhouse because the deal includes clinical-stage companies with upcoming catalysts. Last week, the …

    Published on 3/24/2014
  • AIMing for services

    Why genome editing and services company Horizon chose AIM for its IPO

    Ebb & Flow AIMing for services Horizon Discovery Group plc is following the lead of other U.K. life science services companies by listing on the LSE's AIM rather heading to the U.S. The company says AIM will provide…

    Published on 3/24/2014
  • Horizon's Irish jig

    Why Horizon values Vidara's Irish tax benefit at $100M or more

    Ebb & Flow Horizon's Irish jig Figure: Money Raised in 2014 Horizon Pharma Inc. (NASDAQ:HZNP) thinks Vidara Therapeutics International Ltd.'s lone drug, Actimmune interferon gamma-1b, by itself justifies the $660 …

    Published on 3/24/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993